These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 17497254)
21. A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia. Aizawa Y; Ueda K; Komura S; Washizuka T; Chinushi M; Inagaki N; Matsumoto Y; Hayashi T; Takahashi M; Nakano N; Yasunami M; Kimura A; Hiraoka M; Aizawa Y Int J Cardiol; 2005 Mar; 99(2):343-5. PubMed ID: 15749201 [TBL] [Abstract][Full Text] [Related]
22. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267 [TBL] [Abstract][Full Text] [Related]
23. Molecular diagnostics of catecholaminergic polymorphic ventricular tachycardia using denaturing high-performance liquid chromatography and sequencing. Postma AV; Bhuiyan ZA; Bikker H Methods Mol Med; 2006; 126():171-83. PubMed ID: 16930012 [TBL] [Abstract][Full Text] [Related]
24. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846 [TBL] [Abstract][Full Text] [Related]
25. Involvement of the cardiac ryanodine receptor/calcium release channel in catecholaminergic polymorphic ventricular tachycardia. Marks AR; Priori S; Memmi M; Kontula K; Laitinen PJ J Cell Physiol; 2002 Jan; 190(1):1-6. PubMed ID: 11807805 [TBL] [Abstract][Full Text] [Related]
26. Catecholaminergic polymorphic ventricular tachycardia: a current overview. Leite LR; Henz BD; Macedo PG; Santos SN; Barreto JR; Zanatta A; Fenelon G; Cruz Filho FE Future Cardiol; 2009 Mar; 5(2):191-9. PubMed ID: 19371192 [TBL] [Abstract][Full Text] [Related]
27. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. Postma AV; Denjoy I; Kamblock J; Alders M; Lupoglazoff JM; Vaksmann G; Dubosq-Bidot L; Sebillon P; Mannens MM; Guicheney P; Wilde AA J Med Genet; 2005 Nov; 42(11):863-70. PubMed ID: 16272262 [TBL] [Abstract][Full Text] [Related]
30. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy. Watanabe H; Knollmann BC J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879 [TBL] [Abstract][Full Text] [Related]
31. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves. Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175 [TBL] [Abstract][Full Text] [Related]
32. Genetics of arrhythmogenic right ventricular cardiomyopathy--status quo and future perspectives. Paul M; Schulze-Bahr E; Breithardt G; Wichter T Z Kardiol; 2003 Feb; 92(2):128-36. PubMed ID: 12596074 [TBL] [Abstract][Full Text] [Related]
33. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Marai I; Khoury A; Suleiman M; Gepstein L; Blich M; Lorber A; Boulos M Am J Cardiol; 2012 Jul; 110(1):72-6. PubMed ID: 22481011 [TBL] [Abstract][Full Text] [Related]